Clinical Data

Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout

BioSpace

While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.

Clinical Data Cardiovascular Read full story

pharminent March 30, 2026 (Last updated: March 30, 2026)

BioSpace

While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.

Clinical Data Cardiovascular Read full story

Related Stories

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

You May Have Missed

Alzecure enters collaboration and with Lilly for Alzheimer’s project

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval